Study: Biosimilarities Found Between Yusimry and Humira for Immune, Rheumatic Conditions
Pharmacy Times
JANUARY 5, 2024
Adalimumab-aqvh (Yusimry; Coherus Biosciences) entered the market in July 2023, following approval by the FDA in December 2021.
Let's personalize your content